NCT00449748View on ClinicalTrials.gov

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

Systemic Mastocytosis

Interventions

DRUG

RAD001 (Everolimus)

Oral RAD001 10 mg daily for 30 days

Trial Locations (1)

77030

The University of Texas M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER